Hugues Lucron, Sophie-Guiti Malekzadeh-Milani, Thomas Perouse de Montclos, Alban-Elouen Baruteau, Alberto Mendoza Soto, Gianfranco Butera, Ina Michel-Behnke, Caroline Ovaert, Carles Bautista-Rodriguez, James Bentham, Zakaria Jalal, Pedro Betrian Blasco, Hélène Bouvaist, Marie Vincenti, José Diego Ferreira Matins, Jean-Marc Jellimann, Alessia Callegari, Laurent Bonnemains, Ronan Bonnefoy, Biagio Castaldi, Anne Charbonneau, Claire Dauphin, Bruno Lefort, Stephan Schubert, Mélanie Brard, Olivia Domanski, Charlotte Denis, Julie Wacker, Pascale Maragnes, Clément Karsenty, Petra Loureiro, André Jakob, Sébastien Hascoët, Damien Bonnet
{"title":"Balloon atrioseptostomy for transposition of the great arteries in Europe: characteristics and outcomes.","authors":"Hugues Lucron, Sophie-Guiti Malekzadeh-Milani, Thomas Perouse de Montclos, Alban-Elouen Baruteau, Alberto Mendoza Soto, Gianfranco Butera, Ina Michel-Behnke, Caroline Ovaert, Carles Bautista-Rodriguez, James Bentham, Zakaria Jalal, Pedro Betrian Blasco, Hélène Bouvaist, Marie Vincenti, José Diego Ferreira Matins, Jean-Marc Jellimann, Alessia Callegari, Laurent Bonnemains, Ronan Bonnefoy, Biagio Castaldi, Anne Charbonneau, Claire Dauphin, Bruno Lefort, Stephan Schubert, Mélanie Brard, Olivia Domanski, Charlotte Denis, Julie Wacker, Pascale Maragnes, Clément Karsenty, Petra Loureiro, André Jakob, Sébastien Hascoët, Damien Bonnet","doi":"10.1016/j.rec.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.rec.2024.12.011","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Balloon atrial septostomy (BAS) improves oxygenation in neonates with transposition of the great arteries (TGA) and restrictive foramen ovale. Currently, there is a global shortage of dedicated BAS catheters, while new unmarked catheters have recently become available at some European centers. This study aimed to characterize BAS outcomes using the currently available BAS catheters in Europe.</p><p><strong>Methods: </strong>A 2-year multicenter observational registry was conducted, including all neonates undergoing BAS for TGA. We report preliminary results (September 2022-February 2024) focusing on BAS characteristics and outcomes.</p><p><strong>Results: </strong>A total of 250 BAS procedures were performed in 29 centers. The median neonatal weight was 3.16 kg, and 88% of neonates had a prenatal diagnosis. Most procedures were performed often on the first day of life during working hours (72.8%), mainly in catheterization laboratories (59.2%). Guidance primarily involved ultrasound with or without fluoroscopy. A guidewire was used in 41.2% of procedures. A total of 290 catheters (286 Z-5 or Z-6) were used, achieving an overall BAS success rate of 96%. Complete procedural failure was associated with the use of the umbilical venous route (OR, 3.62; P = .001) and lower-volume catheters (OR, 7.01; P < .001). The occurrence of significant complications (8%; OR, 9.33; P < .001) was associated with complete procedural failure. For complex procedures, significant risk factors were the absence of fluoroscopy (OR, 3.32; P = .001), use of the umbilical venous route (OR, 2.28; P = .005), and lower-volume catheters (OR, 2.43; P = .03).</p><p><strong>Conclusions: </strong>In the current era, BAS can be challenging, and significant complications and complete failures are not uncommon. The use of the umbilical venous route, low-volume BAS catheters, absence of fluoroscopy guidance, and the occurrence of complications negatively impact procedural outcomes.</p>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nader Mankerious, Ralph Toelg, Mohammad Abdelghani, Hector M Garcia-Garcia, Serdar Farhan, Abdelhakim Allali, Stephan Windecker, Thierry Lefèvre, Shigeru Saito, David E Kandzari, Ron Waksman, Gert Richardt, Rayyan Hemetsberger
{"title":"Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials.","authors":"Nader Mankerious, Ralph Toelg, Mohammad Abdelghani, Hector M Garcia-Garcia, Serdar Farhan, Abdelhakim Allali, Stephan Windecker, Thierry Lefèvre, Shigeru Saito, David E Kandzari, Ron Waksman, Gert Richardt, Rayyan Hemetsberger","doi":"10.1016/j.rec.2024.12.009","DOIUrl":"https://doi.org/10.1016/j.rec.2024.12.009","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent (DP-EES).</p><p><strong>Methods: </strong>A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe. The primary endpoints included target lesion failure (TLF)-a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (TLR)-and probable/definite stent thrombosis at 3 years.</p><p><strong>Results: </strong>Patients with moderate-to-severe tortuosity (n=903) had more comorbidities than those with none-to-mild tortuosity (n=1447). Rates of TLF (P=.354), cardiac death (P=.690), TLR (P=.447), and stent thrombosis (P=.084) were similar between the 2 groups, whereas TV-MI occurred more frequently in the moderate-to-severe tortuosity group (P=.031). However, on multivariate analysis, moderate-to-severe tortuosity was not an independent predictor of TV-MI (adjusted HR, 1.06; 95% CI, 0.72-1.55; P=.772). Among patients with moderate-to-severe tortuosity, the use of BP-SES was associated with significantly lower rates of TLF compared with the durable-polymer everolimus-eluting stent (7.8% vs 13.4%; HR, 0.57; 95% CI, 0.37-0.87; P=.009), driven by reductions in TV-MI (5.0% vs 9.2%; HR, 0.54; 95% CI, 0.32-0.90; P=.018) and TLR (2.7% vs 6.1%; HR, 0.45; 95% CI, 0.23-0.90; P=.021).</p><p><strong>Conclusions: </strong>This pooled analysis of the randomized BIOFLOW trials demonstrates that patients with none-to-mild and moderate-to-severe tortuosity have comparable long-term adverse event rates. However, the use of BP-SES in patients with moderate-to-severe tortuosity may help mitigate potential ischemic risks.</p><p><strong>Clinical trial registration: </strong>Clinicaltrials.gov NCT01356888, NCT01939249, NCT02389946.</p>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fernando Aguilar Rodríguez, Javier de Juan Bagudá, Rafael Salguero Bodes, José Luis Bernal Sobrino, Daniel Ferreiro López, Juan F Delgado Jiménez
{"title":"Recurrent readmissions for heart failure: a persistent issue even in patients achieving stability.","authors":"Fernando Aguilar Rodríguez, Javier de Juan Bagudá, Rafael Salguero Bodes, José Luis Bernal Sobrino, Daniel Ferreiro López, Juan F Delgado Jiménez","doi":"10.1016/j.rec.2024.11.014","DOIUrl":"10.1016/j.rec.2024.11.014","url":null,"abstract":"","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Anguita Gámez , Juan L. Bonilla Palomas , Alejandro Recio Mayoral , Rafael González Manzanares , Javier Muñiz García , Nieves Romero Rodríguez , Francisco J. Elola Somoza , Ángel Cequier Fillat , Luis Rodríguez Padial , Manuel Anguita Sánchez
{"title":"Outcomes of patients with heart failure followed in units accredited by the SEC-Excelente-IC quality program according to the type of unit","authors":"María Anguita Gámez , Juan L. Bonilla Palomas , Alejandro Recio Mayoral , Rafael González Manzanares , Javier Muñiz García , Nieves Romero Rodríguez , Francisco J. Elola Somoza , Ángel Cequier Fillat , Luis Rodríguez Padial , Manuel Anguita Sánchez","doi":"10.1016/j.rec.2024.04.017","DOIUrl":"10.1016/j.rec.2024.04.017","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The development of specific heart failure (HF) units has improved the management of patients with this disease due to improved organization and resource management. The Spanish Society of Cardiology (SEC) has defined 3 types of HF units (community, specialized, and advanced) based on their complexity and service portfolio. Our aim was to compare the characteristics, treatment, and outcomes of patients with HF according to the type of unit.</div></div><div><h3>Methods</h3><div>We analyzed data from the <em>SEC-Excelente-IC</em> quality accreditation program registry, with 1716 patients consecutively included in two 1-month cutoffs (March and October) from 2019 to 2021 by 45 SEC-accredited HF units. We compared the characteristics, treatment and 1-year outcomes between the 3 types of units.</div></div><div><h3>Results</h3><div>Of the 1716 patients, 13.2% were treated in community units, 65.9% in specialized units, and 20.9% in advanced units. The rates of mortality (27.5 vs 15.5/100 patients-year; <em>P</em> <!--><<!--> <!-->.001), admissions for HF (39.7 vs 29.2/100 patients-year; <em>P</em> <!-->=<!--> <!-->.019), total decompensations (56.1 vs 40.5/100 patients-year; <em>P</em> <!-->=<!--> <!-->.003), and combined death/admission for HF (45.2 vs 31.4/100 patients-year; <em>P</em> <!-->=<!--> <!-->.005) were higher in community units than in specialized/advanced units. Follow-up in a community unit was an independent predictor of higher mortality and admissions at 1 year.</div></div><div><h3>Conclusions</h3><div>Compared with follow-up by more specialized units, follow-up in a community unit was associated with a higher decompensation rate and increased 1-year mortality.</div></div>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":"78 1","pages":"Pages 12-21"},"PeriodicalIF":7.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Alejandra Restrepo-Córdoba , Przemyslaw Chmielewski , Grażyna Truszkowska , María Luisa Peña-Peña , Miloš Kubánek , Alice Krebsová , Luis R. Lopes , Álvaro García-Ropero , Marco Merlo , Alessia Paldino , Stacey Peters , Ruxandra Jurcut , Roberto Barriales-Villa , Esther Zorio , Mark Hazebroek , Jens Mogensen , Pablo García-Pavía
{"title":"Pregnancy in women with dilated cardiomyopathy genetic variants","authors":"María Alejandra Restrepo-Córdoba , Przemyslaw Chmielewski , Grażyna Truszkowska , María Luisa Peña-Peña , Miloš Kubánek , Alice Krebsová , Luis R. Lopes , Álvaro García-Ropero , Marco Merlo , Alessia Paldino , Stacey Peters , Ruxandra Jurcut , Roberto Barriales-Villa , Esther Zorio , Mark Hazebroek , Jens Mogensen , Pablo García-Pavía","doi":"10.1016/j.rec.2024.04.002","DOIUrl":"10.1016/j.rec.2024.04.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Limited information is available on the safety of pregnancy in patients with genetic dilated cardiomyopathy (DCM) and in carriers of DCM-causing genetic variants without the DCM phenotype. We assessed cardiac, obstetric, and fetal or neonatal outcomes in this group of patients.</div></div><div><h3>Methods</h3><div>We studied 48 women carrying pathogenic or likely pathogenic DCM-associated variants (30 with DCM and 18 without DCM) who had 83 pregnancies. Adverse cardiac events were defined as heart failure (HF), sustained ventricular tachycardia, ventricular assist device implantation, heart transplant, and/or maternal cardiac death during pregnancy, or labor and delivery, and up to the sixth postpartum month.</div></div><div><h3>Results</h3><div>A total of 15 patients, all with DCM (31% of the total cohort and 50% of women with DCM) experienced adverse cardiac events. Obstetric and fetal or neonatal complications were observed in 14% of pregnancies (10 in DCM patients and 2 in genetic carriers). We analyzed the 30 women who had been evaluated before their first pregnancy (12 with overt DCM and 18 without the phenotype). Five of the 12 (42%) women with DCM had adverse cardiac events despite showing NYHA class I or II before pregnancy. Most of these women had a history of cardiac events before pregnancy (80%). Among the 18 women without phenotype, 3 (17%) developed DCM toward the end of pregnancy.</div></div><div><h3>Conclusions</h3><div>Cardiac complications during pregnancy and postpartum were common in patients with genetic DCM and were primarily related to HF. Despite apparently good tolerance of pregnancy in unaffected genetic carriers, pregnancy may act as a trigger for DCM onset in a subset of these women.</div></div>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":"78 1","pages":"Pages 2-9"},"PeriodicalIF":7.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}